Composition-Reinforced Polydopamine Nanoenzyme for Improved Impairment of Prostatitis-Damaged Sexual Behavior and Enhanced Anti-Prostate Cancer

Inflammation is pivotal in the pathogenesis and progression of the most challenging diseases and even cancer. Nanomedicine-based strategy can be referred as a distinct solution to this complicated clinical obstacle by proposing an elaborated combination of effective therapeutic performances on inflammation and cancer. Herein, 2,2,6,6-tetramethylpiperidine-1-oxyl doped polydopamine nanoparticles, termed as TPDA NPs, with the significantly improved reactive oxygen/nitrogen species (RO/NSs) scavenging performance and enhanced photothermal efficiency are designed and synthesized by constructing donor-acceptor pairs, for prostate diseases treatment including anti-inflammation and anti-tumor. Benefiting from mimicking multi-natural enzymes, including superoxide dismutase, catalase, peroxidase, and glutathione peroxidase, TPDA NPs can inhibit the NF-kappa B signaling pathways by downregulating the CD36 expression for the treatment of oxidative stress-induced prostatitis. Especially, TPDA NPs can improve the prostatitis-associated impairment of sexual behavior. By virtue of the enhanced photothermal-conversion efficiency, TPDA NPs ablate prostate cancer and simultaneously decrease inflammatory reaction. Therefore, this work provides a "three birds with one shot" paradigm to utilize rationally designed TPDA NPs for efficient management of prostate diseases. 2,2,6,6-tetramethylpiperidine-1-oxyl doped polydopamine nanoparticles with significantly improved reactive oxygen/nitrogen species (RO/NSs) scavenging performance and enhanced photothermal efficiency are designed and synthesized by constructing donor-acceptor pairs, yielding high performance for impairment of prostatitis-damaged sexual behavior and enhanced anti-prostate cancer.image